APA (7th ed.) Citation

Z, W., F, Y., Q, W., X, X., & Q, L. (2026). Bleeding risk of rivaroxaban and edoxaban with and without amiodarone in atrial fibrillation patients: A prospective cohort study. European journal of clinical pharmacology, 82(3), 75. https://doi.org/10.1007/s00228-026-04004-y

Chicago Style (17th ed.) Citation

Z, Wang, Yang F, Wang Q, Xia X, and Lv Q. "Bleeding Risk of Rivaroxaban and Edoxaban with and Without Amiodarone in Atrial Fibrillation Patients: A Prospective Cohort Study." European Journal of Clinical Pharmacology 82, no. 3 (2026): 75. https://doi.org/10.1007/s00228-026-04004-y.

MLA (9th ed.) Citation

Z, Wang, et al. "Bleeding Risk of Rivaroxaban and Edoxaban with and Without Amiodarone in Atrial Fibrillation Patients: A Prospective Cohort Study." European Journal of Clinical Pharmacology, vol. 82, no. 3, 2026, p. 75, https://doi.org/10.1007/s00228-026-04004-y.